Dermatology Times

OCTOBER 30, 2024

Bob Rhatigan, CEO of Merz Aesthetics, discusses the company’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.

Innovations 74

Innovations Portfolios Education Medical 74

The Dermatology Digest

MARCH 5, 2024

Food and Drug Administration has approved JUVÉDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults age 21 and older. The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face.

Portfolios 74

Portfolios Injections Training Facials 74

The Dermatology Digest

SEPTEMBER 9, 2024

It incorporates Polyglutamic Acid (PGA), a peptide known for its hydrating properties The non-injectable Elastiderm Advanced Filler Concentrate is formulated with Acetyl Hexapeptide-1, to smooth wrinkles and add volume.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

APRIL 1, 2024

“There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.”

Portfolios 36

Portfolios Injections Innovations Sales 36

The Dermatology Digest

MARCH 5, 2024

At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients. I am very encouraged by the initial data from this study, which demonstrate the potential for APG777 as a well-tolerated treatment with a half-life that would support less frequent injections.”

Injections 36

Injections Safety Sustainability Clinic 36

The Dermatology Digest

OCTOBER 1, 2024

Food and Drug Administration (FDA) are aligned on the regulatory pathway for ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX (onabotulinumtoxinA) as the reference product. AEON Biopharma Receives Positive Outcome From FDA in Botox Biosimilar Meeting AEON Biopharma, Inc.

Hydration 36

Hydration Portfolios Office Surgery 36

Aesthetics Advisor

SEPTEMBER 15, 2023

Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Carragelose inactivates the new, rapidly spreading variants and SARS-CoV-2 wildtype with similar efficacy in vitro.

Hospital 69

Hospital Clinic Marketing Medical 69